Menu Back toSession-4-Leveraging-Innovative-Trials-Design-II

Pediatric Drug Development Workshop

Session 4: Leveraging Innovative Trials Design II

Session Chair(s)

Robert Nelson, MD, PhD

Robert Nelson, MD, PhD

  • Senior Director, Pediatric Drug Development (CHILD)
  • Johnson & Johnson, United States
Christina Bucci-Rechtweg, MD

Christina Bucci-Rechtweg, MD

  • Global Head, Maternal Health and Pediatric Regulatory Policy
  • Novartis Pharmaceuticals Corporation, United States
This session will explore the use of innovative trial designs that have the strong potential to accelerate approval of new pediatric therapeutics.

Panelists will be challenged to reflect on strategies that are being discussed with regulatory agencies, and employed across small, focused biotech companies and large pharma to address varying pipeline needs within today’s complex development environment.

Speaker(s)

Edward Connor, MD, MS

Speaker

Edward Connor, MD, MS

  • Professor Emeritus Pediatrics, Microbiology, Immunology, Tropical Medicine
  • George Washington University School of Medicine and Health Sciences, United States
Thomas Miller, PhD

Speaker

Thomas Miller, PhD

  • Vice President and Global Head, Pediatrics
  • Bayer, United States
Andrew Mulberg, MD

Speaker

Andrew Mulberg, MD

  • Senior Vice President
  • Neurogene, United States
Yeruk (Lily) Mulugeta, PharmD

Speaker

Yeruk (Lily) Mulugeta, PharmD

  • Associate Director, Division of Pediatric and Maternal Health, CDER
  • FDA , United States
Robert Nelson, MD, PhD

Speaker

Robert Nelson, MD, PhD

  • Senior Director, Pediatric Drug Development (CHILD)
  • Johnson & Johnson, United States

Contact us

Registration Questions?

Send Email
+1.215.442.6100

Download an Exclusive Session Recording

Industry Perspective: Master Protocols as an Option to Design & Conduct Pediatric Oncology Studies under FDARA

Check out our 2019 Program!